Use of 99mTc Tilmanocept for Imaging Arterial Inflammation
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Aortic 99mTc-Tilmanocept uptake on SPECT/CT scanning in HIV Patients
研究概览
简要总结
The purpose of this study is to measure arterial 99mTc-Tilmanocept uptake using single photon emission computed tomography (SPECT/CT) scanning in HIV infected subjects known to have subclinical coronary atherosclerosis as assessed by contrast-enhanced coronary computed tomography angiography (CCTA).
详细描述
Detailed Description:
Patients with HIV have been shown to have increased atherosclerotic risk compared to age-matched controls, and this risk is thought to be related to increased systemic immune activation. Specifically, systemic immune activation may contribute to destabilizing coronary atherosclerotic plaque, leading to plaque rupture and myocardial infarction. This study is intended to measure arterial uptake of the macrophage specific marker 99mTc-Tilmanocept using single photon emission computed tomography, applied initially to a group of HIV-infected patients with known subclinical coronary atherosclerosis on CCTA. Moreover, traditional markers of CVD risk and inflammatory markers will be assessed in relation to CV imaging outcomes. Positive findings in the index HIV group with known subclinical atherosclerosis will prompt subsequent study of three comparison groups, as above.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Aortic 99mTc-Tilmanocept uptake on SPECT/CT scanning in HIV Patients
时间窗: within 6 weeks of screening visit
次要结局
- Aortic plaque burden and morphology on CCTA in HIV Patients(within 6 weeks of screening visit)
- Traditional markers of cardiovascular disease (CVD) risk and inflammatory markers in relation to cardiovascular imaging outcomes(within 6 weeks of screening visit)
- Imaging assessments in the coronary vasculature in HIV patients(within 6 weeks of screening visit)
- Comparison of imaging assessments b/ HIV patients w/ known subclinical atherosclerosis, HIV patients w/o known subclinical atherosclerosis, non HIV patients w/ known subclinical atherosclerosis and non HIV patients w/o known subclinical atherosclerosis(within 6 weeks of screening visit)
- 99mTc-Tilmanocept uptake on SPECT/CT in regions other than the aorta(within 6 weeks of screening visit)
研究者
Steven K. Grinspoon, MD
Professor of Medicine
Massachusetts General Hospital